- Home
- KALA
KALA
KALA BIO Inc.
as 07-04-2025 10:34am EST
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | ARLINGTON |
| Market Cap: | 26.2M | IPO Year: | 2017 |
| Target Price: | $14.00 | AVG Volume (30 days): | 71.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.92 - $11.20 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of KALA BIO Inc. (KALA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Iwicki Mark T | KALA | Director | Jun 24 '25 | Sell | $4.01 | 13,227 | $53,040.27 | 258,433 | |
| Bazemore Todd | KALA | SEE REMARKS | Jun 24 '25 | Sell | $4.01 | 4,058 | $16,272.58 | 83,699 | |
| Brazzell Romulus K | KALA | SEE REMARKS | Jun 24 '25 | Sell | $4.01 | 5,251 | $21,056.51 | 82,698 | |
| Reumuth Mary | KALA | CHIEF FINANCIAL OFFICER | Jun 24 '25 | Sell | $4.01 | 3,631 | $14,560.31 | 62,100 | |
| Iwicki Mark T | KALA | Director | Jun 3 '25 | Sell | $3.74 | 21,732 | $81,277.68 | 258,433 | |
| Bazemore Todd | KALA | SEE REMARKS | Jun 3 '25 | Sell | $3.74 | 3,390 | $12,678.60 | 83,699 | |
| Kharabi Darius | KALA | CHIEF BUSINESS OFFICER | Jun 3 '25 | Sell | $3.74 | 730 | $2,730.20 | 67,077 | |
| Brazzell Romulus K | KALA | SEE REMARKS | Jun 3 '25 | Sell | $3.74 | 3,687 | $13,789.38 | 82,698 | |
| Reumuth Mary | KALA | CHIEF FINANCIAL OFFICER | Jun 3 '25 | Sell | $3.74 | 2,850 | $10,659.00 | 62,100 |
Latest KALA BIO Inc. News
KALA Breaking Stock News: Dive into KALA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
KALA BIO to Present at Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
4 months ago
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
GlobeNewswire
5 months ago
KALA BIO Announces Chief Executive Officer Transition
GlobeNewswire
6 months ago
KALA BIO Announces $10,750,000 Private Placement
GlobeNewswire
7 months ago
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
8 months ago
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Compare KALA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALA KALA BIO Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.